MedTrace Logo

Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma

NCT04083079 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2019-09-10

No results posted yet for this study

Summary

This is a pharmacoeconomic research to explore the cost-effectiveness of PEG-rhG-CSF and rhG-CSF in prophylactic treatment of neutropenia in lymphoma patients. It should provide more scientific basis for clinical decision-making.

Conditions

  • Lymphoma, Non-Hodgkin
  • Granulocyte Colony-Stimulating Factor
  • Cost-Benefit Analysis

Interventions

DRUG

PEG-rhG-CSF

Patients will be given PEG-rhG-CSF for primary/secondary prevention each cycle.

DRUG

rhG-CSF

Patients will be given rhG-CSF for either primary/secondary prevention or treatment once any neutropenia each cycle.

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-01
Primary Completion
2021-08-01
Completion
2022-04-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04083079 on ClinicalTrials.gov